Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 17, 2025 08:00 ET | Source: T-knife Therapeutics

T-knife Therapeutics Files Clinical Trial Application for Phase 1 ATLAS Trial for TK-6302, a Supercharged PRAME-targeted T Cell Receptor Therapy

-- Preclinical data with TK-6302 has shown best-in-class anti-tumor efficacy, demonstrating its potential to elicit deep and durable responses in diverse solid tumor indications with high unmet need ...
November 07, 2025 09:00 ET | Source: T-knife Therapeutics

T-knife Therapeutics Presents Preclinical Data on PRAME-Targeted TK-6302 Highlighting its Potential as a Promising, Category-leading Therapy at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

-- Comprehensive TK-6302 data demonstrate preclinical efficacy and safety, supporting clinical readiness, alongside established scalable manufacturing --TK-6302 Clinical Trial Application planned in...
October 30, 2025 08:00 ET | Source: T-knife Therapeutics

T-knife Therapeutics Announces Four Upcoming Data Presentations on PRAME-Targeted TK-6302 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

-- Posters will review product characterization and manufacturing data on T-knife’s lead program, TK-6302, a supercharged PRAME T cell receptor therapy that is advancing towards the clinic, with the...
October 07, 2025 09:00 ET | Source: T-knife Therapeutics

T-knife Therapeutics Presents Preclinical Data Highlighting the Transformative Potential of the MyT™ Platform to Discover and Develop Next-Generation TCR Therapies to Treat Solid Tumors at the European Society of Gene & Cell Therapy (ESGCT) 2025 Annual Congress

-- Integrating a computational workflow that leverages multi-omics data with a proprietary, humanized in vivo screening platform, T-knife identified highly immunogenic solid-tumor antigens not...
July 01, 2025 08:00 ET | Source: T-knife Therapeutics

T-knife Therapeutics Appoints Christoph Broja to its Board of Directors

SAN FRANCISCO and BERLIN, July 01, 2025 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight...
April 25, 2025 13:00 ET | Source: T-knife Therapeutics

T-knife Therapeutics Presents Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting Demonstrating a Potential Best-in-Class PRAME Targeted TCR-T Therapy

– TK-6302, a supercharged PRAME targeting TCR-T therapy, demonstrates best-in-class preclinical anti-tumor efficacy as compared to current clinical stage PRAME TCR-T approaches, providing the...
March 25, 2025 16:30 ET | Source: T-knife Therapeutics

T-knife Therapeutics Announces Five Presentations at American Association for Cancer Research (AACR) Annual Meeting

Multiple presentations demonstrate that T-knife’s proprietary next-generation technologies address important challenges with current cell therapy constructs, including boosting T cell fitness and...
February 20, 2025 08:00 ET | Source: T-knife Therapeutics

T-knife Therapeutics Welcomes Dr. Sophie Papa to its Board of Directors

SAN FRANCISCO and BERLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight...
February 12, 2025 08:00 ET | Source: T-knife Therapeutics

T-knife Therapeutics to Participate in Two Investor Conferences in March

SAN FRANCISCO and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight...
November 06, 2023 08:00 ET | Source: T-knife Therapeutics

T-knife Therapeutics Announces the Appointment of Simone Silva Steiner, Ph.D., as Chief Technical Operations Officer

SAN FRANCISCO and BERLIN, Nov. 06, 2023 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that...